Alongside its results, the company announced a significant product launch. On August 11, Pfizer rolled out its ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer's revenue grew 7.1% to ₹604 crore from ₹563 crore, while EBITDA increased 18.1% to ₹209.7 crore from ₹177.6 crore in ...

Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Key inflation data and earnings from major companies such as HAL, ONGC, and Suzlon are expected to set the near-term tone.

Pfizer's share price gained today after the company announced the launch of its next-generation 20-valent pneumococcal ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker ...